B

Biofrontera
D

BFRI

0.92010
USD
0.01
(0.57%)
Market Closed
Volume
15,398
EPS
-4
Div Yield
-
P/E
1
Market Cap
7,130,049
News

Title: Biofrontera

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.